Peptide immunotherapy for childhood allergy - addressing translational challenges

Clinical and Translational Allergy

Volumn 1, Issue 1, 2011, Pages 1-9

  Mackenzie, Karen J ^a,b   Anderton, Stephen M ^a,b   Schwarze, Jürgen ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Allergy; Children; Peptide Immunotherapy

Indexed keywords

HLA ANTIGEN; INTERLEUKIN 10; PEPTIDE;

ADULT; ALLERGENICITY; ALLERGIC REACTION; ALLERGY; ANAPHYLAXIS; ANTIGENIC VARIATION; CD4+ T LYMPHOCYTE; CELL ADAPTATION; CELL DELETION; CELL PROLIFERATION; CELL REGULATION; CELLULAR PARAMETERS; CHILD; CHILDHOOD; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE EXACERBATION; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; LATE ASTHMATIC REACTION; NONHUMAN; PEPTIDE IMMUNOTHERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK ASSESSMENT; SENSITIZATION; SIGNAL TRANSDUCTION; SPECIFIC IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 85006325322     PISSN: None     EISSN: 20457022     Source Type: Journal    
DOI: 10.1186/2045-7022-1-13     Document Type: Review

References (85)

1. Punekar YS, Sheikh A: Establishing the sequential progression of multiple allergic diagnoses in a UK birth cohort using the General Practice Research Database. Clin Exp Allergy. 2009, 39: 1889-1895. 10.1111/j.1365-2222.2009.03366.x.
2. Barnes PJ, Jonsson B, Klim JB: The costs of asthma. Eur Respir J. 1996, 9: 636-642. 10.1183/09031936.96.09040636.
3. Holgate ST: A look at the pathogenesis of asthma: the need for a change in direction. Discovery medicine. 2010, 9: 439-447.
4. Leckie MJ, Brinke At, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response. Lancet. 2000, 356: 2144-2148. 10.1016/S0140-6736(00)03496-6.
5. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID: Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009, 360: 973-984. 10.1056/NEJMoa0808991.
6. Sears MR, Greene JM, Willan AR, Wiecek EM, Taylor DR, Flannery EM, Cowan JO, Herbison GP, Silva PA, Poulton R: A longitudinal, population-based, cohort study of childhood asthma followed to adulthood. N Engl J Med. 2003, 349: 1414-1422. 10.1056/NEJMoa022363.
7. Boyle RJ, Tang MLK: Can allergic diseases be prevented prenatally?. Allergy. 2006, 61: 1423-1431. 10.1111/j.1398-9995.2006.01113.x.
8. Warner JO: The early life origins of asthma and related allergic disorders. Arch Dis Child. 2004, 89: 97-102. 10.1136/adc.2002.013029.
9. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S: Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001, 31: 1392-1397. 10.1046/j.1365-2222.2001.01161.x.
10. Larche M, Wraith DC: Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med. 2005, 11: S69-76. 10.1038/nm1226.
11. Akdis M, Akdis CA: Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009, 8: 645-660. 10.1038/nrd2653.
12. Lloyd CM, Hessel EM: Functions of T cells in asthma: more than just Th2 cells. Nat Rev Immunol. 2010, 10: 838-848. 10.1038/nri2870.
13. Noon L: Prophylactic innoculation against hay fever. Lancet. 1911, i: 1572-1573.
14. Frew AJ: Allergen immunotherapy. J Allergy Clin Immunol. 2010, 125: S306-313. 10.1016/j.jaci.2009.10.064.
15. Norman PS: Immunotherapy: 1999-2004. J Allergy Clin Immunol. 2004, 113: 1013-1023. 10.1016/j.jaci.2004.03.020.
16. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JGR, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R: Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010, 125: 131-138. 10.1016/j.jaci.2009.10.035.
17. Jacobsen L, Valovirta E: How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma?. Curr Opin Allergy Clin Immunol. 2007, 7: 556-560. 10.1097/ACI.0b013e3282f1d67e.
18. Caubet JC, Eigenmann PA: Late side-effects during systemic immunotherapy in children. Allergy. 2008, 63: 1561-1562. 10.1111/j.1398-9995.2008.01868.x.
19. Peavy RD, Metcalfe DD: Understanding the mechanisms of anaphylaxis. Curr Opin Allergy Clin Immunol. 2008, 8: 310-315. 10.1097/ACI.0b013e3283036a90.
20. Borchers A, Keen C, Gershwin M: Fatalities following allergen immunotherapy. Clin Rev Allergy Immunol. 2004, 27: 147-158. 10.1385/CRIAI:27:2:147.
21. Anderton SM: Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology. 2001, 104: 367-376. 10.1046/j.1365-2567.2001.01324.x.
22. Liu GY, Wraith DC: Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice--implications for autoimmunity. Int Immunol. 1995, 7: 1255-1263. 10.1093/intimm/7.8.1255.
23. Wraith DC: Therapeutic peptide vaccines for treatment of autoimmune diseases. Immunol Lett. 2009, 122: 134-136. 10.1016/j.imlet.2008.11.013.
24. Larché M: Peptide immunotherapy for allergic diseases. Allergy. 2007, 62: 325-331. 10.1111/j.1398-9995.2006.01309.x.
25. Hochweller K, Anderton SM: Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo. Eur J Immunol. 2005, 35: 1086-1096. 10.1002/eji.200425891.
26. Gabrysova L, Nicolson KS, Streeter HB, Verhagen J, Sabatos-Peyton CA, Morgan DJ, Wraith DC: Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med. 2009, 206: 1755-1767. 10.1084/jem.20082118.
27. Koffeman EC, Genovese M, Amox D, Keogh E, Santana E, Matteson EL, Arthur K, Jerry AM, Michael HS, James OP, Joan MB, Alan JK, Rodrigo S, Francis B, Carolyn D, Theo van den B, Femke van W, Xiao Z, Peter Z, Tho L, Berent AP, Gary CC, Salvatore A: Epitope-specific immunotherapy of rheumatoid arthritis: Clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. Arthritis Rheum. 2009, 60: 3207-3216. 10.1002/art.24916.
28. Ohnmacht C, Pullner A, King SBS, Drexler I, Meier S, Brocker T, Voehringer D: Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med. 2009, 206: 549-559. 10.1084/jem.20082394.
29. Kunkel D, Kirchhoff D, Volkmer-Engert R, Radbruch A, Scheffold A: Sensitive visualization of peptide presentation in vitro and ex vivo. Cytometry Part A. 2003, 54A: 19-26. 10.1002/cyto.a.10055.
30. Haase C, Yu L, Eisenbarth G, Markholst H: Antigen-dependent immunotherapy of non-obese diabetic mice with immature dendritic cells. Clin Exp Immunol. 2010, 160: 331-339. 10.1111/j.1365-2249.2010.04104.x.
31. Lambrecht BN, Hammad H: Biology of lung dendritic cells at the origin of asthma. Immunity. 2009, 31: 412-424. 10.1016/j.immuni.2009.08.008.
32. Gabryšová L, Wraith DC: Antigenic strength controls the generation of antigen-specific IL-10-secreting T regulatory cells. Eur J Immunol. 2010, 40: 1386-1395. 10.1002/eji.200940151.
33. Janssen EM, van Oosterhout AJM, Nijkamp FP, van Eden W, Wauben MHM: The efficacy of immunotherapy in an experimental murine model of allergic asthma is related to the strength and site of T cell activation during immunotherapy. J Immunol. 2000, 165: 7207-7214.
34. Ryan KR, Patel SD, Stephens LA, Anderton SM: Death, adaptation and regulation: The three pillars of immune tolerance restrict the risk of autoimmune disease caused by molecular mimicry. J Autoimmun. 2007, 29: 262-271. 10.1016/j.jaut.2007.07.014.
35. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WLG, Stern LJ, Gronlund H, van Hage M, Reynolds CJ, Boyton RJ, Cobbold SP, Kay AB, Altmann DM, Lloyd CM, Larche M: Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med. 2009, 206: 1535-1547. 10.1084/jem.20082901.
36. Fellrath J-M, Kettner A, Dufour N, Frigerio C, Schneeberger D, Leimgruber A, Corradin G, Spertini F: Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial. J Allergy Clin Immunol. 2003, 111: 854-861. 10.1067/mai.2003.1337.
37. Liblau RS, Tisch R, Shokat K, Yang X, Dumont N, Goodnow CC, McDevitt HO: Intravenous injection of soluble antigen induces thymic and peripheral T-cells apoptosis. Proc Natl Acad Sci USA. 1996, 93: 3031-3036. 10.1073/pnas.93.7.3031.
38. Schwartz RH: T Cell Anergy. Annu Rev Immunol. 2003, 21: 305-334. 10.1146/annurev.immunol.21.120601.141110.
39. Pape KA, Merica R, Mondino A, Khoruts A, Jenkins MK: Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance. J Immunol. 1998, 160: 4719-4729.
40. Verhoef A, Alexander C, Kay AB, Larche M: T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med. 2005, 2: e78-10.1371/journal.pmed.0020078.
41. Smith TRF, Alexander C, Kay AB, Larché M, Robinson DS: Cat allergen peptide immunotherapy reduces CD4+ T cell responses to cat allergen but does not alter suppression by CD4+ CD25+ T cells: a double-blind placebo-controlled study. Allergy. 2004, 59: 1097-1101. 10.1111/j.1398-9995.2004.00601.x.
42. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell. 2008, 133: 775-787. 10.1016/j.cell.2008.05.009.
43. van Rijt LS, Vos N, Willart M, Muskens F, Tak PP, van der Horst C, Hoogsteden HC, Lambrecht BN: Persistent activation of dendritic cells after resolution of allergic airway inflammation breaks tolerance to inhaled allergens in mice. Am J Respir Crit Care Med. 2011, 184: 303-311. 10.1164/rccm.201101-0019OC.
44. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H: Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005, 6: 1219-1227. 10.1038/ni1265.
45. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M: In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med. 2008, 205: 2887-2898. 10.1084/jem.20080193.
46. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008, 121: 1467-1472. 10.1016/j.jaci.2008.03.013. e1461
47. Francis JN, Till SJ, Durham SR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003, 111: 1255-1261. 10.1067/mai.2003.1570.
48. Moldaver D, Larche M: Immunotherapy with peptides. Allergy. 2011, 66: 784-791. 10.1111/j.1398-9995.2011.02610.x.
49. Norman PS, Ohman LN, Long AA, Creticos PS, Gefter MA, Z S: Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996, 154: 1623-1628.
50. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT: The Safety and Efficacy of ALLERVAX CAT in Cat Allergic Patients. Clin Immunol. 1999, 93: 222-231. 10.1006/clim.1999.4795.
51. Pene J, Desroches A, Paradis L, Lebel B, Farce M, Nicodemus C, Yssel H, Bousquet J: Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol. 1998, 102: 571-578. 10.1016/S0091-6749(98)70294-5.
52. Simons FER, Imada M, Li Y, Watson WTA, HayGlass KT: Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol. 1996, 8: 1937-1945. 10.1093/intimm/8.12.1937.
53. Oldfield WLG, Kay AB, Larche M: Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol. 2001, 167: 1734-1739.
54. Alexander C, Tarzi M, Larche M, Kay AB: The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy. 2005, 60: 1269-1274. 10.1111/j.1398-9995.2005.00885.x.
55. Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W, Birnbaum J, Bodzenta-Lukaszyk A, Bonifazi F, Bucher C, Campi P, Darsow U, Egger C, Haeberli G, Hawranek T, Kucharewicz I, Küchenhoff H, Lang R, Quercia O, Reider N, Severino M, Sticherling M, Sturm GJ, Wüthrich B: Predictors of side effects during the buildup phase of venom immunotherapy for hymenoptera venom allergy: The importance of baseline serum tryptase+. J Allergy Clin Immunol. 2010, 126: 105-111. 10.1016/j.jaci.2010.04.025.
56. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, K B: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998, 101: 747-754. 10.1016/S0091-6749(98)70402-6.
57. Tarzi M, Klunker S, Texier C, Verhoef A, Stapel SO, Akdis CA, Maillere B, Kay AB, Larché M: Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy. 2006, 36: 465-474. 10.1111/j.1365-2222.2006.02469.x.
58. Prickett SR, Voskamp AL, Dacumos-Hill A, Symons K, Rolland JM, O'Hehir RE: Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. J Allergy Clin Immunol. 2011, 127: 608-615. 10.1016/j.jaci.2010.09.027. e601-605
59. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L, Comi G, Kappos L, Oger J, Panitch H, Rae-Grant A, Castaldo J, Eckert N, Guarnaccia JB, Mills P, Johnson G, Calabresi PA, Pozzilli C, Bastianello S, Giugni E, Witjas T, Cozzone P, Pelletier J, Pohlau D, Przuntek H, Hoffmann V, Bever C, Katz E, Clanet M, Berry I, Brassat D, Brunet I, Edan G, Duquette P, Radue E-W, Schott D, Lienert C, Taksaoui A, Rodegher M, Filippi M, Evans A, Bourgouin P, Zijdenbos A, Salem S, Ling N, Alleva D, Johnson E, Gaur A, Crowe P, Liu X-J: Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med. 2000, 6: 1176-1182. 10.1038/80525.
60. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med. 2000, 6: 1167-1175. 10.1038/80516.
61. Janssen EM, Wauben MHM, Jonker EH, Hofman G, Van Eden W, Nijkamp FP, VanOosterhout AJM: Opposite effects of immunotherapy with ovalbumin and the immunodominant T-cell epitope on airway eosinophilia and hyperresponsiveness in a murine model of allergic asthma. Am J Respir Cell Mol Biol. 1999, 21: 21-29.
62. Haselden BM, Barry Kay A, Larche M: Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999, 189: 1885-1894. 10.1084/jem.189.12.1885.
63. Larche M, Haselden BM, Oldfield WLG, Shirley K, North J, Meng Q, Robinson DS, Ying S, Kay AB: Mechanisms of T cell peptide epitope-dependent late asthmatic reactions. Int Arch Allergy Immunol. 2001, 124: 272-275. 10.1159/000053730.
64. Oseroff C, Sidney J, Kotturi MF, Kolla R, Alam R, Broide DH, Wasserman SI, Weiskopf D, McKinney DM, Chung JL, Petersen A, Grey H, Peters B, Sette A: Molecular determinants of T cell epitope recognition to the common timothy grass allergen. J Immunol. 2010, 185: 943-955. 10.4049/jimmunol.1000405.
65. Munthe-Kaas MC, Carlsen KL, Carlsen KH, Egeland T, Håland G, Devulapalli CS, Akselsen H, Undlien D: HLA Dr-Dq haplotypes and the TNFA-308 polymorphism: associations with asthma and allergy. Allergy. 2007, 62: 991-998. 10.1111/j.1398-9995.2007.01377.x.
66. Schuppan D, Junker Y, Barisani D: Celiac disease: from pathogenesis to novel therapies. Gastroenterology. 2009, 137: 1912-1933. 10.1053/j.gastro.2009.09.008.
67. Caillat-Zucman S: Molecular mechanisms of HLA association with autoimmune diseases. Tissue Antigens. 2009, 73: 1-8. 10.1111/j.1399-0039.2008.01167.x.
68. Larché M: Of cats and men: immunodominance and the role of HLA-DP/DQ. Clin Exp Allergy. 2008, 38: 1709-1711. 10.1111/j.1365-2222.2008.03112.x.
69. Friedl H, Spangfort , Schou , Breiteneder , Joost Van N: Identification of a highly promiscuous and an HLA allele-specific T-cell epitope in the birch major allergen Bet v 1: HLA restriction, epitope mapping and TCR sequence comparisons. Clin Exp Allergy. 1999, 29: 478-487. 10.1046/j.1365-2222.1999.00489.x.
70. Kobayashi H, Wood M, Song Y, Appella E, Celis E: Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 2000, 60: 5228-5236.
71. Kinnunen T, Jutila K, Kwok WW, Rytkönen-Nissinen M, Immonen A, Saarelainen S, Närvänen A, Taivainen A, Virtanen T: Potential of an altered peptide ligand of lipocalin allergen Bos d 2 for peptide immunotherapy. J Allergy Clin Immunol. 2007, 119: 965-972. 10.1016/j.jaci.2007.01.011.
72. Alexander C, Ying S, B Kay A, Larché M: Fel d 1-derived T cell peptide therapy induces recruitment of CD4+CD25+; CD4+ interferon-γ+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy. 2005, 35: 52-58. 10.1111/j.1365-2222.2005.02143.x.
73. Kuchroo VK, Greer JM, Kaul D, Ishioka G, Franco A, Sette A, Sobel RA, Lees MB: A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol. 1994, 153: 3326-3336.
74. Sakurai Y, Brand DD, Tang B, Rosloniec EF, Stuart JM, Kang AH, Myers LK: Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther. 2006, 8: R150-10.1186/ar2043.
75. Anderton SM, Manickasingham SP, Burkhart C, Luckcuck TA, Holland SJ, Lamont AG, Wraith DC: Fine specificity of the myelin-reactive T cell repertoire: implications for TCR antagonism in autoimmunity. J Immunol. 1998, 161: 3357-3364.
76. Leech MD, Chung C, Culshaw A, Anderton SM: Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. Eur J Immunol. 2007, 37: 3576-3581. 10.1002/eji.200737148.
77. Gonnella P, Del Nido P, McGowan F: Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of Stat 6 genes in BALB/CJ mice. J Clin Immunol. 2009, 29: 434-443. 10.1007/s10875-009-9290-z.
78. Radulovic S, Wilson D, Calderon M, Durham S: Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011, 66: 740-752. 10.1111/j.1398-9995.2011.02583.x.
79. Oldfield WLG, Larché M, Kay AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002, 360: 47-53. 10.1016/S0140-6736(02)09332-7.
80. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, 62: 943-948. 10.1111/j.1398-9995.2007.01451.x.
81. Amin HS, Liss GM, Bernstein DI: Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006, 117: 169-175. 10.1016/j.jaci.2005.10.010.
82. Zuberbier T, Bachert C, Bousquet PJ, Passalacqua G, Walter Canonica G, Merk H, Worm M, Wahn U, Bousquet J: GA2LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010, 65: 1525-1530. 10.1111/j.1398-9995.2010.02474.x.
83. Beyer M, Bartz H, Hörner K, Doths S, Koerner-Rettberg C, Schwarze J: Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection. J Allergy Clin Immunol. 2004, 113: 127-133. 10.1016/j.jaci.2003.10.057.
84. Tsitoura DC, Kim S, Dabbagh K, Berry G, Lewis DB, Umetsu DT: Respiratory infection with influenza A virus interferes with the induction of tolerance to aeroallergens. J Immunol. 2000, 165: 3484-3491.
85. O'Donnell DR, Openshaw PJ: Anaphylactic sensitization to aeroantigen during respiratory virus infection. Clin Exp Allergy. 1998, 28: 1501-1508. 10.1046/j.1365-2222.1998.00438.x.